Ed at Pharmalot has the story:
http://www.pharmalot.com/2012/10/boehringer-pays-95m-for-off-label-marketing/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Pharmalot+%28Pharmalot%29
Showing posts with label Boehringer Ingelheim. Show all posts
Showing posts with label Boehringer Ingelheim. Show all posts
Thursday, October 25, 2012
Tuesday, August 25, 2009
Are Boehringer cutting 600 US rep jobs?
That's what Insider hears. Thirty percent - gone!
Apparently horrible trial results for currently promoted drugs combined with Mirapex going off patent and losing Flomax to generic as well has led to a cut of 600 or more reps in the USA.
Apparently horrible trial results for currently promoted drugs combined with Mirapex going off patent and losing Flomax to generic as well has led to a cut of 600 or more reps in the USA.
Notifications were on Tuesday morning via a phone call to impacted reps.
Monday, October 06, 2008
BI / Pfizer - Spiriva: clinical trials, ain't they a bitch!?
Spiriva, marketed by Pfizer and Boehringer Ingelheim, offered no advantage over an inhaled placebo for moderate-to-very-severe chronic obstructive pulmonary disease, or COPD, researchers reported on Sunday.
More
Also, remember this.
Looks like Spiriva might be the next Vytorin - sales-wise!
More
Also, remember this.
Looks like Spiriva might be the next Vytorin - sales-wise!
Thursday, May 15, 2008
Boehringer Ingelheim - clinical trials, ain't they a bitch?!
Said through gritted teeth:
"We are proud to have sponsored the PRoFESS study," said Dr. Thor Voigt, Senior Vice President, Medicine and Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.
"We set out to advance the understanding of strategies for recurrent stroke prevention and will continue to evaluate the PRoFESS data to help physicians make more informed treatment decisions."
The Trial:
PRoFESS (Prevention Regimen For Effectively avoiding Second Strokes) was designed to examine the effects of different prevention regimens on recurrent stroke, including the antiplatelet agent AGGRENOX versus clopidogrel and the efficacy of MICARDIS, an antihypertensive, compared to placebo in preventing recurrent stroke in the presence of background standard antihypertensive therapy. The trial was a randomized, double-blind, placebo-controlled clinical study that included 20,332 patients from 695 sites in 35 countries, with a four-year follow-up of patients.
PRoFESS is a collaborative effort between academia and the sponsor, Boehringer Ingelheim. Co-funders of the telmisartan arm of the study in selected countries are Bayer Schering Pharma and GlaxoSmithKline.
The Results:
Read them and weep - if you work for BI, that is!
Boehringer Ingelheim just blew up not one, but two of their own drugs with one trial !
Bad day, huh?
Hat tip: The Caped Crusader
"We are proud to have sponsored the PRoFESS study," said Dr. Thor Voigt, Senior Vice President, Medicine and Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.
"We set out to advance the understanding of strategies for recurrent stroke prevention and will continue to evaluate the PRoFESS data to help physicians make more informed treatment decisions."
The Trial:
PRoFESS (Prevention Regimen For Effectively avoiding Second Strokes) was designed to examine the effects of different prevention regimens on recurrent stroke, including the antiplatelet agent AGGRENOX versus clopidogrel and the efficacy of MICARDIS, an antihypertensive, compared to placebo in preventing recurrent stroke in the presence of background standard antihypertensive therapy. The trial was a randomized, double-blind, placebo-controlled clinical study that included 20,332 patients from 695 sites in 35 countries, with a four-year follow-up of patients.
PRoFESS is a collaborative effort between academia and the sponsor, Boehringer Ingelheim. Co-funders of the telmisartan arm of the study in selected countries are Bayer Schering Pharma and GlaxoSmithKline.
The Results:
Read them and weep - if you work for BI, that is!
Boehringer Ingelheim just blew up not one, but two of their own drugs with one trial !
Bad day, huh?
Hat tip: The Caped Crusader
Thursday, April 24, 2008
Boehringer Ingelheim - Pradaxa: anatomy of a launch contd.
Back story here.
Chandler Chicco Agency offshoot Litmus, based in London, is in charge of the global PR programme for Pradaxa.
The account is led by Camilla Bull, who is well-versed in this area: she used to work on AstraZeneca's Exanta, an anti-VTE drug that was withdrawn two years ago after it was found to cause liver problems.
Wave Healthcare Communications handles media relations for Pradaxa in the UK and Wave founding director Rod Ball leads the account.
Chandler Chicco Agency offshoot Litmus, based in London, is in charge of the global PR programme for Pradaxa.
The account is led by Camilla Bull, who is well-versed in this area: she used to work on AstraZeneca's Exanta, an anti-VTE drug that was withdrawn two years ago after it was found to cause liver problems.
Wave Healthcare Communications handles media relations for Pradaxa in the UK and Wave founding director Rod Ball leads the account.
Anthony Y. Lauw is the Senior International Product Manager for Pradaxa at Boehringer Ingelheim.
Monday, April 21, 2008
Boehringer Ingelheim - Pradaxa: anatomy of a launch
A new oral direct thrombin inhibitor Pradaxa® (dabigatran etexilate) was launched in the UK today.
It is approved for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective total hip or total knee replacement surgery.
More information here.
European approval was based on data from the phase III RE-NOVATE and RE-MODEL studies, which indicated that both 150mg and 220mg of Pradaxa were as effective and safe as injectable enoxaparin (40 mg) in preventing VTE and all cause mortality following total hip replacement surgery and total knee replacement surgery in the RE-NOVATE and RE-MODEL trials, respectively.
Both studies reported a low incidence and severity of major bleeding, similar to enoxaparin. In addition, the rates of ALT elevations > 3x times the upper limit of normal were reported to be low and comparable to enoxaparin.
The PR flaks were hard a work.
It made the BBC Breakfast TV show.
And a charity was there ready to welcome it.
The UK charity Lifeblood's medical director, Dr Beverley Hunt, said: "The prevention of blood clots with blood thinners after surgery is not done well in the UK."
"The need for and potential impact of a generally well-tolerated oral anticoagulant that does not require monitoring is profound."
Here's what they're saying about it on their website.
Hmmmm. Watch this space.
It is approved for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective total hip or total knee replacement surgery.
More information here.
European approval was based on data from the phase III RE-NOVATE and RE-MODEL studies, which indicated that both 150mg and 220mg of Pradaxa were as effective and safe as injectable enoxaparin (40 mg) in preventing VTE and all cause mortality following total hip replacement surgery and total knee replacement surgery in the RE-NOVATE and RE-MODEL trials, respectively.
Both studies reported a low incidence and severity of major bleeding, similar to enoxaparin. In addition, the rates of ALT elevations > 3x times the upper limit of normal were reported to be low and comparable to enoxaparin.
The PR flaks were hard a work.
It made the BBC Breakfast TV show.
And a charity was there ready to welcome it.
The UK charity Lifeblood's medical director, Dr Beverley Hunt, said: "The prevention of blood clots with blood thinners after surgery is not done well in the UK."
"The need for and potential impact of a generally well-tolerated oral anticoagulant that does not require monitoring is profound."
Here's what they're saying about it on their website.
Hmmmm. Watch this space.
Subscribe to:
Posts (Atom)